JAB-2485 is under clinical development by Jacobio Pharmaceuticals Group and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how JAB-2485’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

JAB-2485 overview

JAB-2485 is under development for the treatment of RB1 deficient tumors , solid tumor, triple negative breast cancer and small-cell lung cancer. It acts by targeting aurora kinase A. It is administered through oral route.

Jacobio Pharmaceuticals Group overview

Jacobio Pharmaceuticals Group (Jacobio Pharma) discovers and develops monotherapies to treat cancer. The company is investigating JAB-3068 program for the treatment of solid tumors, esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC), and non-small cell lung cancer (NSCLC); JAB-3312 drug against pancreatic cancer and KRAS mutation in colorectal cancer, osimertinib progressed and KRAS G12C mutation in NSCLC. It is also evaluating JAB-8263 drug to treat solid tumors, myelofibrosis and acute myeloid leukemia (AML). Jacobio Pharma works in partnership with entrepreneurs, biotechnology and pharmaceutical companies. The company operates with research and development centers in Beijing and Shanghai, China and Boston, the US. Jacobio Pharma is headquartered in Beijing, China.

For a complete picture of JAB-2485’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.